Contact
searchSearch
HMP Global

Multiple Sclerosis News

a physician fills out a discharge form while speaking to a patient
Research Summary
Early Ocrelizumab Shows Sustained Long-Term Benefit in Relapsing MS
10/06/2026
Maria Mantas
Treatment with ocrelizumab for up to 10 years was associated with sustained relapse control and minimal disability accrual in patients with relapsing MS, according to phase 3 findings.
Treatment with ocrelizumab for up to 10 years was associated with sustained relapse control and minimal disability accrual in patients with relapsing MS, according to phase 3 findings.
Treatment with ocrelizumab for...
10/06/2026
Neurology
A nurse and a doctor review information on a computer in a lab clinical study research trial
News
Fenebrutinib for Multiple Sclerosis Returns Significant Phase III Results
03/04/2026
Brionna Mendoza
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1...
03/04/2026
Neurology
a colorful illustration of the brain
News
Five-Year Ublituximab Efficacy Sustained in Relapsing MS Trial
02/23/2026
Maria Mantas
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Ublituximab provided sustained...
02/23/2026
Neurology
A doctor looks at a brain scan
News
Obexelimab for Relapsing MS Meets Primary Endpoint in Phase 2 Trial
11/04/2025
Brionna Mendoza
In the Phase 2 MoonStone trial of obexelimab in relapsing multiple sclerosis (rMS), the investigational drug met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhacing (GdE) T1 hyperintense lesions over week 8 and...
In the Phase 2 MoonStone trial of obexelimab in relapsing multiple sclerosis (rMS), the investigational drug met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhacing (GdE) T1 hyperintense lesions over week 8 and...
In the Phase 2 MoonStone trial...
11/04/2025
Neurology
an older woman sits on a couch looking out the window
News
Menopause Not Associated With Disease Progression in MS
10/10/2025
Brionna Mendoza
Menopause was not found to drive disease progression in multiple sclerosis (MS) in women at midlife. Results from the longitudinal cohort study were published in JAMA Neurology.
Menopause was not found to drive disease progression in multiple sclerosis (MS) in women at midlife. Results from the longitudinal cohort study were published in JAMA Neurology.
Menopause was not found to drive...
10/10/2025
Neurology
a head in profile with a heart over where the brain would be against a teal background
News
Multiple Sclerosis May Increase Risk for Alzheimer Disease
07/30/2025
Brionna Mendoza
Multiple sclerosis (MS) may increase the risk of developing Alzheimer disease (AD), according to an analysis of genetic data published in Neurodegenerative Disease Management.
Multiple sclerosis (MS) may increase the risk of developing Alzheimer disease (AD), according to an analysis of genetic data published in Neurodegenerative Disease Management.
Multiple sclerosis (MS) may...
07/30/2025
Neurology
A teddy bear against a blue background wearing a mask and stethoscope.
News
In Pediatric Onset Multiple Sclerosis, Biological Aging May Be Accelerated
06/11/2025
Brionna Mendoza
A new study suggests that biological aging may be accelerated in children living with multiple sclerosis (MS).
A new study suggests that biological aging may be accelerated in children living with multiple sclerosis (MS).
A new study suggests that...
06/11/2025
Neurology
illustration of the brain in white lines against a black background
News
Biomarker Combo Predicts MS in Patients With Radiologically Isolated Syndrome
06/09/2025
Jolynn Tumolo
Researchers have identified a combination of factors that confers a 58.3% risk of the development of multiple sclerosis (MS) over 5 years in people with radiologically isolated syndrome (pwRIS).
Researchers have identified a combination of factors that confers a 58.3% risk of the development of multiple sclerosis (MS) over 5 years in people with radiologically isolated syndrome (pwRIS).
Researchers have identified a...
06/09/2025
Neurology
a human hand holds a Vitamin D supplement pill against a background of clouds in the sky on a sunny day
News
High-Dose Vitamin D Eases Disease Activity in Patients With Multiple Sclerosis
03/20/2025
Jolynn Tumolo
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced...
03/20/2025
Neurology
News
Long COVID Symptoms Persist in Individuals With Multiple Sclerosis, Study Finds
02/10/2025
Lisa Kuhns, PhD, MD
Individuals with multiple sclerosis (MS) experience an ongoing impact of post-COVID-19 symptoms, revealing a significant overlap between post-acute sequelae of SARS-CoV-2 infection (PASC) and MS-related symptoms.
Individuals with multiple sclerosis (MS) experience an ongoing impact of post-COVID-19 symptoms, revealing a significant overlap between post-acute sequelae of SARS-CoV-2 infection (PASC) and MS-related symptoms.
Individuals with multiple...
02/10/2025
First Report Managed Care

About Us

Neurology Learning Network is an online resource for the latest developments in clinical practice, providing a customized experience for readers to stay informed about the topics that matter most to them.

We are also the official media partner of Alzheimer's Disease and Cognitive Disorders Symposium

News

a patient laying in a hospital bed holds hands with a healthcare provider
Research Summary
Hospital-Associated Delirium Linked to Worse Cognitive Trajectories
11/04/2026
Maria Mantas
Delirium documented within 30 days of hospitalization was associated with a significantly higher risk of mild cognitive impairment and dementia, according to longitudinal cohort findings.
Delirium documented within 30 days of hospitalization was associated with a significantly higher risk of mild cognitive impairment and dementia, according to longitudinal cohort findings.
Delirium documented within 30...
11/04/2026
Neurology
older adult resting hands on cane
Research Summary
Vascular Risk Factors Associated With Late-Onset Epilepsy in Older Adults
10/22/2026
Maria Mantas
Several vascular risk factors, including smoking, hypertension, diabetes and prior stroke, were associated with LOE in older adults, according to pooled analysis findings.
Several vascular risk factors, including smoking, hypertension, diabetes and prior stroke, were associated with LOE in older adults, according to pooled analysis findings.
Several vascular risk factors,...
10/22/2026
Neurology
trees with leaves falling to represent dementia progression
News
Global Dementia Cases Projected to Double by 2050
10/15/2026
Maria Mantas
A meta-analysis of 38,418 participants across 18 countries or territories estimated 11.4 million new dementia cases globally in 2023, with annual incidence projected to reach 24.7 million by 2050.
A meta-analysis of 38,418 participants across 18 countries or territories estimated 11.4 million new dementia cases globally in 2023, with annual incidence projected to reach 24.7 million by 2050.
A meta-analysis of 38,418...
10/15/2026
Neurology
a physician fills out a discharge form while speaking to a patient
Research Summary
Early Ocrelizumab Shows Sustained Long-Term Benefit in Relapsing MS
10/06/2026
Maria Mantas
Treatment with ocrelizumab for up to 10 years was associated with sustained relapse control and minimal disability accrual in patients with relapsing MS, according to phase 3 findings.
Treatment with ocrelizumab for up to 10 years was associated with sustained relapse control and minimal disability accrual in patients with relapsing MS, according to phase 3 findings.
Treatment with ocrelizumab for...
10/06/2026
Neurology
a hand points to a specific spot on a brain scan
News
P2Y12 Inhibitors Linked to Worse Intracerebral Hemorrhage Outcomes in Nationwide Study
07/13/2026
Maria Mantas
A nationwide cohort study found that prior use of P2Y12 inhibitors, either alone or combined with aspirin, was associated with more severe presentation and worse hospital outcomes in patients with spontaneous ICH.
A nationwide cohort study found that prior use of P2Y12 inhibitors, either alone or combined with aspirin, was associated with more severe presentation and worse hospital outcomes in patients with spontaneous ICH.
A nationwide cohort study found...
07/13/2026
Neurology
a researcher holds up a test tube of blood
News
Plasma p-tau217/Aβ42 Test Accuracy Reduced in Patients With Traumatic Brain Injury
07/06/2026
Maria Mantas
Plasma p-tau217/Aβ42 ratio accurately detected amyloid-PET positivity in veterans without traumatic brain injury (TBI), but accuracy declined significantly in those with prior TBI. 
Plasma p-tau217/Aβ42 ratio accurately detected amyloid-PET positivity in veterans without traumatic brain injury (TBI), but accuracy declined significantly in those with prior TBI. 
Plasma p-tau217/Aβ42 ratio...
07/06/2026
Neurology
doctor holds hands with an older woman patient sitting on the couch
News
Higher Parity May Accelerate Preclinical Alzheimer’s Changes in Postmenopausal Women
06/29/2026
Maria Mantas
A longitudinal study reports that parity may modify the relationship between Alzheimer disease (AD) pathology and brain aging in cognitively unimpaired postmenopausal women.
A longitudinal study reports that parity may modify the relationship between Alzheimer disease (AD) pathology and brain aging in cognitively unimpaired postmenopausal women.
A longitudinal study reports...
06/29/2026
Neurology
an older woman sits on a couch looking out the window
Research Summary
Frontal Release Signs Linked to Future Dementia Risk in Older Adults
06/17/2026
Maria Mantas
The presence of frontal release signs (FRS), primitive reflexes that reemerge with neurodegeneration or brain injury, may help identify older adults at increased risk for future cognitive decline, according to a cohort study.
The presence of frontal release signs (FRS), primitive reflexes that reemerge with neurodegeneration or brain injury, may help identify older adults at increased risk for future cognitive decline, according to a cohort study.
The presence of frontal release...
06/17/2026
Neurology
a doctor reviews brain scans
News
Reperfusion-Guided Blood Pressure Strategy May Improve Stroke Outcomes
06/09/2026
Maria Mantas
A multicenter randomized clinical trial found that reperfusion-guided systolic blood pressure (BP) management after successful endovascular therapy improved 90-day functional outcomes compared with guideline-recommended care.
A multicenter randomized clinical trial found that reperfusion-guided systolic blood pressure (BP) management after successful endovascular therapy improved 90-day functional outcomes compared with guideline-recommended care.
A multicenter randomized...
06/09/2026
Neurology
a strand of RNA
News
SKY-0515 Shows Sustained Biomarker Reductions in Huntington’s Disease
06/01/2026
Maria Mantas
SKY-0515, an investigational oral RNA splicing modifier, reduced mutant huntingtin (mHTT) protein levels in blood by up to 69% and PMS1 mRNA by up to 26% in a phase 1/2 Huntington’s disease (HD) trial. 
SKY-0515, an investigational oral RNA splicing modifier, reduced mutant huntingtin (mHTT) protein levels in blood by up to 69% and PMS1 mRNA by up to 26% in a phase 1/2 Huntington’s disease (HD) trial. 
SKY-0515, an investigational...
06/01/2026
Neurology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use